12th February 2009

Further funding secured in a key year for "Clinic-ready" NovaBiotics

Novabiotics confirms that it has successfully completed its first funding round of 2009; securing £610,000 from existing and new investors. This brings the total of equity funding and grant support raised by the Company within the past 6 months to over £1.5m; funds that will support the clinical phase of development for NovaBiotics' lead antifungal product, Novexatin^®